Black Diamond Therapeutics, Inc.

Informe acción NasdaqGS:BDTX

Capitalización de mercado: US$115.2m

Black Diamond Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Black Diamond Therapeutics disminuyan a un ritmo anual de 17.9%, mientras que sus ingresos anuales crecerán a un ritmo de 70.7% por año. Se espera que el BPA disminuya en un 8.4% al año.

Información clave

-17.9%

Tasa de crecimiento de los beneficios

-8.37%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.1%
Tasa de crecimiento de los ingresos70.7%
Rentabilidad financiera futuran/a
Cobertura de analistas

Good

Última actualización01 Jun 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Jul 01

Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 25

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Summary Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding. Risks include competitive combination regimens and the need for future data to confirm silevertinib’s clinical and regulatory viability. Read the full article on Seeking Alpha
Artículo de análisis • May 04

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Mar 25

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Summary Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals. I expect BDTX to reach $3.00 per share soon as the market absorbs the seller's shares and recognizes the partnership's value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 13

Black Diamond Therapeutics: In Decline, But Why?

Summary Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash position, supporting ongoing research and development efforts without immediate capital concerns. Strengths include a robust pipeline and innovative approach, while risks involve clinical trial uncertainties and market competition. Bottom-line summary: Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech sector risks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 30

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Summary Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX’s $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535. Key milestones, including first-line NSCLC trial results and FDA feedback, are expected in Q1 2025, positioning BDTX-1535 for Phase 3 trials. At a P/B ratio of 1.3, BDTX trades at a discount compared to its sector, presenting a speculative “Buy” opportunity ahead of significant catalysts. Read the full article on Seeking Alpha
Artículo de análisis • Oct 30

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 08

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Summary Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic. The global non-small cell lung cancer market is projected to reach $36.9 million by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Summary Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability. Read the full article on Seeking Alpha
Artículo de análisis • May 21

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Black Diamond...
Artículo de análisis • Jan 31

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 12

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Summary Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535. Read the full article on Seeking Alpha
Artículo de análisis • Oct 26

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • May 05

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Artículo de análisis • Jan 16

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Oct 02

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Jul 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:BDTX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2028N/A-9416-958
12/31/2027N/A-70-44-648
12/31/20266-40-42-409
3/31/2026N/A-43-34-34N/A
12/31/202570223030N/A
9/30/202570212121N/A
6/30/202570141818N/A
3/31/20257051212N/A
12/31/2024N/A-70-62-62N/A
9/30/2024N/A-73-61-61N/A
6/30/2024N/A-81-68-68N/A
3/31/2024N/A-80-68-68N/A
12/31/2023N/A-82-67-67N/A
9/30/2023N/A-84-75-75N/A
6/30/2023N/A-83-73-73N/A
3/31/2023N/A-87-77-77N/A
12/31/2022N/A-91-85-85N/A
9/30/2022N/A-96-88-87N/A
6/30/2022N/A-109-99-97N/A
3/31/2022N/A-121-107-104N/A
12/31/2021N/A-126-103-100N/A
9/30/2021N/A-122-94-92N/A
6/30/2021N/A-105-78-77N/A
3/31/2021N/A-85-65-65N/A
12/31/2020N/A-67-52-52N/A
9/30/2020N/A-55-44-44N/A
6/30/2020N/A-46-38-38N/A
3/31/2020N/A-44-29-29N/A
12/31/2019N/A-35N/A-25N/A
9/30/2019N/A-28N/A-20N/A
6/30/2019N/A-22N/A-16N/A
3/31/2019N/A-11N/A-13N/A
12/31/2018N/A-9N/A-8N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BDTX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BDTX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BDTX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (70.7% al año) de BDTX crezcan más rápidamente que los del mercado US (12.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (70.7% al año) de BDTX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BDTX se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/07/05 05:44
Precio de las acciones al final del día2026/07/02 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Black Diamond Therapeutics, Inc. está cubierta por 17 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Zhiqiang ShuBerenberg
Arlinda LeeCanaccord Genuity
Ilya ZubkovFreedom Broker